Skip to Content
Merck
  • Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities.

Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities.

Journal of biochemical and molecular toxicology (2018-07-12)
Sujay Gaikwad, Avik Chakraborty, Sukeshani Salwe, Vainav Patel, Savita Kulkarni, Sharmila Banerjee
ABSTRACT

Anaplastic thyroid carcinoma (ATC) requires more innovative approaches as the current regimes for therapy are inadequate, also most anticancer drugs cause general suppression of physiological functions. However, therapy with limited nontarget tissue damage is desirable. In the present study, we show prooxidant ability of ascorbic acid, which enhances cytotoxicity induced by juglone. We decipher that juglone-ascorbate combination induces reactive oxygen species-mediated apoptosis leading to cell death in ARO cell line originated from ATC. This combination also affects enzyme activity of catalase, glutathione reductase, and superoxide dismutase destabilizing redox balance in cell and thereby making juglone effective at a lower dose. We also show that juglone-ascorbate combination suppresses cell migration, invasion, and expression of tumor-promoting, and angiogenic genes in ARO cell line, thereby disrupting epithelial-mesenchymal transition ability of the cells. Overall, we show that ascorbic acid increases cytotoxic potency of juglone through redox cycling when used in synergy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pentostatin, ≥95% (HPLC)
Sigma-Aldrich
5-Hydroxy-1,4-naphthoquinone, 97%
Sigma-Aldrich
MISSION® esiRNA, targeting human SOD1